莫西沙星注射液致低血钾1例分析

doi:10.19803/j.1672-8629.2022.03.26

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (3): 342-344.
DOI: 10.19803/j.1672-8629.2022.03.26

莫西沙星注射液致低血钾1例分析

杨桂玲, 赵牡丹, 高义玲, 王贝, 朱明辉^*

东南大学医学院附属南京同仁医院,江苏南京 211102

收稿日期:2020-05-17 出版日期:2022-03-15 发布日期:2022-03-16
通讯作者: ^*朱明辉,男,学士,主任药师,临床药学。E-mail: zhumh@njtrh.org
作者简介:杨桂玲,女,学士,副主任药师,临床药学。

One case of hypokalemia caused by moxifloxacin injection and literature analysis

YANG Guiling, ZHAO Mudan, GAO Yiling, WANG Bei, ZHU Minghui^*

The Affiliated Nanjing Tongren Hospital of Southeast University Medical College, Nanjing Jiangsu 211102, China

Received:2020-05-17 Online:2022-03-15 Published:2022-03-16

摘要/Abstract

摘要： 目的探讨莫西沙星注射液致低血钾的机制,为临床安全合理使用莫西沙星提供参考。方法分析该患者接受莫西沙星注射液治疗后发生低血钾的诊疗过程。结果患者静脉滴注莫西沙星注射液1周后出现低血钾（2.78 mmol·L^-1）,予停用莫西沙星注射液,静脉及口服补钾后,血钾恢复（4.41 mmol·L^-1）。结论静脉滴注莫西沙星注射液可能导致低血钾,治疗中应予以重视。

关键词: 莫西沙星, 低钾血症, 药品不良反应

Abstract: Objective To explore the mechanism by which hypokalemia is caused by moxifloxacin injection so as to provide reference for clinical rational and safe use of moxifloxacin. Methods The diagnosis and treatment process of one case of hypokalemia after moxifloxacin injection was analyzed. Results Symptoms of hypokalemia (2.78 mmol·L^-1) occurred one week after intravenous injection of moxifloxacin. After moxifloxacin injection was withdrawn and intravenous and oral potassium supplementation was started, the level of potassium returned to normal (4.41 mmol·L^-1). Conclusion Intravenous injection of moxifloxacin may lead to hypokalemia, which deserves more attention in clinic.

Key words: moxifloxacin, hypokalemia, adverse drug reactions

中图分类号:

R994.11

杨桂玲, 赵牡丹, 高义玲, 王贝, 朱明辉. 莫西沙星注射液致低血钾1例分析[J]. 中国药物警戒, 2022, 19(3): 342-344.

YANG Guiling, ZHAO Mudan, GAO Yiling, WANG Bei, ZHU Minghui. One case of hypokalemia caused by moxifloxacin injection and literature analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 342-344.

参考文献

[1] Chinese Society of Respiratory Medicine. Guidelines for diagnosis and treatment of community-acquired pneumonia in Chinese adults (2016 Edition)[J]. Chinese Journal of Tuberculosis and Respiratory Medicine(中华结核和呼吸杂志), 2016, 39(4): 253-279.
[2] ZHANG TM.Observation on the efficacy of potassium chloride and sodium chloride injection in preventing drug-induced hypokalemia in the elderly[J]. Prescription Drugs in China(中国处方药), 2019, 17(2): 105-106.
[3] LIN D.Analysis of a case of hypokalemia caused by quinolones[J]. International Medical and Health Herald(国际医药卫生导报), 2011, 17(17): 2150-2151.
[4] Drug Safety Supervision Department of State Food and Drug Administration, National Center for Adverse Drug Reaction. Manual for adverse drug reaction reporting and monitoring[S] . 2012: 49.
[5] LAPI F, TUCCORI M, MOTOLA D, et al.Safety profile of the fluoroquinolones[J]. Drug Safety, 2010, 33(5): 353.
[6] XIAO DD, ZHAO GK, CHEN M.Literature analysis of 134 cases of adverse reactions caused by moxifloxacin[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(5): 287-291, 301.
[7] CHOI HK, JUNG JA, FUJITA T, et al.Population pharmacokinetic-pharmacodynamic analysis to compare the effect of moxifloxacin on QT interval prolongation between healthy Korean and Japanese subjects[J]. Clinical Therapeutics, 2016, 38(12): 2610-2621.
[8] FALCONE C, COMPOSTELLA L, CAMARDO A, et al.Hypokalemia during antibiotic treatment for bone and joint infections[J]. European Journal of Orthopaedic Surgery & Traumatology, 2018, 28(3): 389-395.
[9] WANG WJ, CHEN FJ.A case of hypokalemia caused by gatifloxacin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(10): 631-631.
[10] ALEXANDROU AJ, DUNCAN RS, SULLIVAN A, et al.Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin[J]. British Journal of Pharmacology, 2006, 147(8): 905-916.
[11] Will you have hypokalemia with ciprofloxacin—from FDA reports[EB/OL]. [2020-06-06].https://www.ehealthme.com/ds/ciprofloxacin/hypokalemia/.
[12] ZIETSE R, ZOUTENDIJK R, HOORN EJ.Fluid, electrolyte and acid-base disorders associated with antibiotic therapy[J]. Nature Reviews Nephrology, 2009, 5(4): 193-202.
[13] WU XY, TAN LN, YANG J, et al.Drug-induced hypokalemia and its clinical treatment[J]. Modern Drug Application in China(中国现代药物应用), 2009, 3(17): 200-202.
[14] WU WF, DU LY, DONG JL.Etiology and treatment progress of hypokalemia[J]. Journal of Clinical Rational Drug Use(临床合理用药杂志), 2018, 11(1): 180-181.
[15] MARIA LUKÁCS KROGAGER, CHRISTIAN TORP-PEDERSEN, RIKKE NØRMARK MORTENSEN, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data[J]. European Heart Journal, 2017, 38(2): 104-112.
[16] ABO-SALEM E, FOWLER JC, ATTARI M, et al.Antibiotic-induced cardiac arrhythmias[J]. Cardiovascular Therapeutics, 2014, 32(1): 19-25.
[17] BENNETT AC, BENNETT CL, WITHERSPOON BJ, et al.An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency[J]. Expert Opinion on Drug Safety, 2019, 18(11): 1055-1063.
[18] TIAN CH.Thoughts on promoting adverse drug reaction monitoring in medical institutions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2016,13(5): 272-274.

莫西沙星注射液致低血钾1例分析

One case of hypokalemia caused by moxifloxacin injection and literature analysis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.